ATF3 and Fra1 have opposite functions in JNK- and ERK-dependent DNA damage responses

DNA Repair

Volumn 7, Issue 3, 2008, Pages 487-496

  Hamdi, Mohamed ^a   Popeijus, Herman E ^a   Carlotti, Françoise ^a   Janssen, Josephine M ^a   van der Burgt, Corina ^a   Cornelissen Steijger, Paulien ^a   van de Water, Bob ^b   Hoeben, Rob C ^a   Matsuo, Koichi ^c   van Dam, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Apoptosis; ATF3; Cell cycle; DNA damage; Fra1; MAP kinases

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FRA 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRAIT; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; ULTRAVIOLET RADIATION;

ACTIVATING TRANSCRIPTION FACTOR 3; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CISPLATIN; CYCLIN-DEPENDENT KINASE 2; DNA DAMAGE; GLIOBLASTOMA; HUMANS; LENTIVIRUS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE 8; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-FOS; S PHASE; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; ULTRAVIOLET RAYS;

EID: 39149098775     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2007.12.004     Document Type: Article

References (55)

1. Chaney S.G., and Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. 88 (1996) 1346-1360
2. Weston C.R., and Davis R.J. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12 (2002) 14-21
3. Camps M., Nichols A., and Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 14 (2000) 6-16
4. Sanchez-Perez I., Martinez-Gomariz M., Williams D., Keyse S.M., and Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19 (2000) 5142-5152
5. Hamdi M., Kool J., Cornelissen-Steijger P., Carlotti F., Popeijus H.E., van der B.C., Janssen J.M., Yasui A., Hoeben R.C., Terleth C., Mullenders L.H., and van Dam H. DNA damage in transcribed genes induces apoptosis via the JNK pathway and the JNK-phosphatase MKP-1. Oncogene 24 (2005) 7135-7144
6. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
7. Wang X., Martindale J.L., and Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275 (2000) 39435-39443
8. Mandic A., Viktorsson K., Heiden T., Hansson J., and Shoshan M.C. The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 11 (2001) 11-19
9. Dent P., Yacoub A., Fisher P.B., Hagan M.P., and Grant S. MAPK pathways in radiation responses. Oncogene 22 (2003) 5885-5896
10. Wisdom R. AP-1: one switch for many signals. Exp. Cell Res. 253 (1999) 180-185
11. Potapova O., Basu S., Mercola D., and Holbrook N.J. Protective role for c-Jun in the cellular response to DNA damage. J. Biol. Chem. 276 (2001) 28546-28553
12. Wagner E.F. AP-1-introductory remarks. Oncogene 20 (2001) 2334-2335
13. Shaulian E., and Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4 (2002) E131-E136
14. Shaulian E., and Karin M. AP-1 in cell proliferation and survival. Oncogene 20 (2001) 2390-2400
15. van Dam H., and Castellazzi M. Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene 20 (2001) 2453-2464
16. Bakiri L., Takada Y., Radolf M., Eferl R., Yaniv M., Wagner E.F., and Matsuo K. Role of heterodimerization of c-Fos and Fra1 proteins in osteoclast differentiation. Bone 40 (2007) 867-875
17. Hai T., Wolfgang C.D., Marsee D.K., Allen A.E., and Sivaprasad U. ATF3 and stress responses. Gene Expr. 7 (1999) 321-335
18. Murphy L.O., Smith S., Chen R.H., Fingar D.C., and Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat. Cell Biol. 4 (2002) 556-564
19. Casalino L., De Cesare D., and Verde P. Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol. Cell Biol. 23 (2003) 4401-4415
20. Vial E., and Marshall C.J. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci. 116 (2003) 4957-4963
21. Ventura J.J., Kennedy N.J., Lamb J.A., Flavell R.A., and Davis R.J. c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol. Cell Biol. 23 (2003) 2871-2882
22. Jochum W., Passegue E., and Wagner E.F. AP-1 in mouse development and tumorigenesis. Oncogene 20 (2001) 2401-2412
23. Ameyar-Zazoua M., Wisniewska M.B., Bakiri L., Wagner E.F., Yaniv M., and Weitzman J.B. AP-1 dimers regulate transcription of the p14/p19ARF tumor suppressor gene. Oncogene 24 (2005) 2298-2306
24. Choi B.Y., Choi H.S., Ko K., Cho Y.Y., Zhu F., Kang B.S., Ermakova S.P., Ma W.Y., Bode A.M., and Dong Z. The tumor suppressor p16(INK4a) prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat. Struct. Mol. Biol. 12 (2005) 699-707
25. Yan C., Lu D., Hai T., and Boyd D.D. Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 24 (2005) 2425-2435
26. Potapova O., Haghighi A., Bost F., Liu C., Birrer M.J., Gjerset R., and Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272 (1997) 14041-14044
27. Macleod K., Mullen P., Sewell J., Rabiasz G., Lawrie S., Miller E., Smyth J.F., and Langdon S.P. Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 65 (2005) 6789-6800
28. Nakatani K., Nakamura M., Uzawa K., Wada T., Seki N., Tanzawa H., and Fujita S. Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol. Rep. 13 (2005) 709-714
29. Ouwens D.M., de Ruiter N.D., van der Zon G.C., Carter A.P., Schouten J., van der B.C., Kooistra K., Bos J.L., Maassen J.A., and van Dam H. Growth factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. EMBO J. 21 (2002) 3782-3793
30. van Dam H., Duyndam M., Rottier R., Bosch A., Vries-Smits L., Herrlich P., Zantema A., Angel P., and van der Eb A.J. Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J. 12 (1993) 479-487
31. van Dam H., Offringa R., Meijer I., Stein B., Smits A.M., Herrlich P., Bos J.L., and van der Eb A.J. Differential effects of the adenovirus E1A oncogene on members of the AP-1 transcription factor family. Mol. Cell Biol. 10 (1990) 5857-5864
32. Passegue E., Jochum W., Behrens A., Ricci R., and Wagner E.F. JunB can substitute for Jun in mouse development and cell proliferation. Nat. Genet. 30 (2002) 158-166
33. Kool J., Hamdi M., Cornelissen-Steijger P., van der Eb A.J., Terleth C., and van Dam H. Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2. Oncogene 22 (2003) 4235-4242
34. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
35. Carlotti F., Bazuine M., Kekarainen T., Seppen J., Pognonec P., Maassen J.A., and Hoeben R.C. Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol. Ther. 9 (2004) 209-217
36. Slack D.N., Seternes O.M., Gabrielsen M., and Keyse S.M. Distinct binding determinants for ERK2/p38alpha and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. J. Biol. Chem. 276 (2001) 16491-16500
37. Gruda M.C., Kovary K., Metz R., and Bravo R. Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity. Oncogene 9 (1994) 2537-2547
38. Bartek J., Lukas C., and Lukas J. Checking on DNA damage in S phase. Nat. Rev. Mol. Cell Biol. 5 (2004) 792-804
39. Kawauchi J., Zhang C., Nobori K., Hashimoto Y., Adachi M.T., Noda A., Sunamori M., and Kitajima S. Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription. J. Biol. Chem. 277 (2002) 39025-39034
40. Mechta F., Lallemand D., Pfarr C.M., and Yaniv M. Transformation by ras modifies AP1 composition and activity. Oncogene 14 (1997) 837-847
41. Allan A.L., Albanese C., Pestell R.G., and LaMarre J. Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J. Biol. Chem. 276 (2001) 27272-27280
42. Mashima T., Udagawa S., and Tsuruo T. Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis. J. Cell Physiol. 188 (2001) 352-358
43. Perez S., Vial E., van Dam H., and Castellazzi M. Transcription factor ATF3 partially transforms chick embryo fibroblasts by promoting growth factor-independent proliferation. Oncogene 20 (2001) 1135-1141
44. Vial E., Sahai E., and Marshall C.J. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 4 (2003) 67-79
45. Shirsat N.V., and Shaikh S.A. Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells. Exp. Cell Res. 291 (2003) 91-100
46. Hartman M.G., Lu D., Kim M.L., Kociba G.J., Shukri T., Buteau J., Wang X., Frankel W.L., Guttridge D., Prentki M., Grey S.T., Ron D., and Hai T. Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol. Cell Biol. 24 (2004) 5721-5732
47. Kranenburg O., van der Eb A.J., and Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 15 (1996) 46-54
48. Esashi F., Christ N., Gannon J., Liu Y., Hunt T., Jasin M., and West S.C. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 434 (2005) 598-604
49. Huang H., Regan K.M., Lou Z., Chen J., and Tindall D.J. CDK2-dependent phosphorylation of FOXO1 as an apoptotic response to DNA damage. Science 314 (2006) 294-297
50. Sorensen C.S., Hansen L.T., Dziegielewski J., Syljuasen R.G., Lundin C., Bartek J., and Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 7 (2005) 195-201
51. MacLaren A., Black E.J., Clark W., and Gillespie D.A. c-Jun-deficient cells undergo premature senescence as a result of spontaneous DNA damage accumulation. Mol. Cell Biol. 24 (2004) 9006-9018
52. Hayakawa J., Depatie C., Ohmichi M., and Mercola D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J. Biol. Chem. 278 (2003) 20582-20592
53. Hayakawa J., Mittal S., Wang Y., Korkmaz K.S., Adamson E., English C., Ohmichi M., McClelland M., and Mercola D. Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol. Cell 16 (2004) 521-535
54. Schreiber M., Baumann B., Cotten M., Angel P., and Wagner E.F. Fos is an essential component of the mammalian UV response. EMBO J. 14 (1995) 5338-5349
55. Christmann M., Tomicic M.T., Origer J., Aasland D., and Kaina B. c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF. Nucl. Acids Res. 34 (2006) 6530-6539